Test Price
2,800 AED✅ Home Collection Available
GARS1 Gene CMT2D Next-Generation Sequencing (NGS) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% clinical sensitivity for SNVs, indels, and CNVs via ISO 9001:2015 accredited NGS platform.
- Premium Logistics: Complimentary VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Oversight: Post-test telephonic interpretation and genetic counseling provided by a Consultant Medical Genetics specialist.
- Insurance & Billing: Direct billing verification and insurance pre-authorization facilitated via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The GARS1 gene test employs advanced Next-Generation Sequencing (NGS) to identify pathogenic variants responsible for Charcot-Marie-Tooth disease type 2D (CMT2D), a progressive hereditary motor and sensory neuropathy. This assay provides comprehensive coverage of the GARS1 gene, detecting point mutations, small insertion/deletion events, and large copy number variants with exceptional precision. A definitive molecular diagnosis facilitates accurate genetic counseling, prognosis, and family planning decisions.
| Feature | Our Test: GARS1 NGS | Alternative: Sanger Sequencing |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) – full gene coverage including intronic regions | Sanger sequencing of coding exons only |
| Precision | Detects SNVs, indels, and large CNVs; >99.9% sensitivity | Detects most point mutations; may miss large deletions or deep intronic variants |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Price | 2,800 AED | Approx. 3,500 AED |
Physician Insight & Safety Protocols
“A comprehensive molecular genetic analysis of GARS1 is indispensable for confirming a clinical suspicion of CMT2D. It facilitates precise family counseling and prognostic discussions. Nonetheless, clinical acumen and electrophysiological correlation remain the cornerstones of comprehensive patient evaluation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Medication & Clinical Advisory
Critical Reminder: Do not adjust or cease any prescribed pharmacological interventions without explicit direction from your primary healthcare provider. Genetic diagnostics provide supportive data for clinical decision-making and should not be interpreted in isolation.
Patient Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection:
- Active febrile illness or systemic infection at the time of collection (rescheduling is recommended).
- Allogeneic blood transfusion or hematopoietic stem cell transplantation within the preceding 4 weeks (may compromise test accuracy).
- Inability to provide written informed consent or complete the mandated pre-test genetic counseling session.
Emergency Red Flags:
- Acute respiratory difficulty or rapid progression of muscle weakness.
- Sudden loss of ambulation or severe, unrelenting neuropathic pain.
- Immediate evaluation at the nearest hospital emergency department is required if any of these symptoms occur.
Patient FAQ & Clinical Guidance
1. What is the GARS1 gene test and who should consider it?
This NGS-based genetic test detects disease-causing variants in the GARS1 gene, which is associated with Charcot-Marie-Tooth disease type 2D (CMT2D). It is recommended for individuals presenting with progressive distal muscle weakness, atrophy, or sensory loss, particularly when family history suggests an autosomal dominant inheritance pattern. A definitive genetic diagnosis enables targeted management and family risk assessment.
2. How is the sample collected for the GARS1 NGS test?
Sample collection is performed via a standard peripheral blood draw (whole blood in EDTA tube) or through an alternative validated matrix such as extracted genomic DNA or a dried blood spot on an FTA card. Our certified phlebotomists conduct the collection through our VIP Mobile Phlebotomy service, operating daily from 8 AM to 11 PM. The specimen is transported under strict temperature-controlled conditions to our CAP-accredited laboratory.
3. Is the GARS1 genetic test covered by insurance in the UAE?
Insurance coverage for genetic testing varies significantly between policies and providers. Our dedicated billing team verifies your specific insurance benefits and direct billing eligibility via WhatsApp. We facilitate all necessary pre-authorization documentation to ensure transparent and hassle-free financial processing.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with the UAE’s comprehensive legal framework for genetic data and health information. This test is performed under the governance of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical safety and patient consent protocols strictly adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | GARS1 Gene CMT2D Next-Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Days (3–4 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted Genomic DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | G60.0 |
| LOINC Code | 95050-2 |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians